Top

07-07-2017 | Psoriatic arthritis | Article

Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate

Journal: Clinical Rheumatology

Authors: Luisa Costa, Ennio Lubrano, Roberta Ramonda, Maria Sole Chimenti, Maristella Vezzù, Fabio M. Perrotta, Antonio Del Puente, Rosario Peluso, Paolo Bottiglieri, Mariagrazia Lorenzin, Flavia Sunzini, Md Abud Darda, Ugo Fiocco, Roberto Perricone, Leonardo Punzi, Raffaele Scarpa, Francesco Caso

Publisher: Springer London

Abstract

Psoriatic arthritis (PsA) is an inflammatory arthropathy, associated with skin and/or nail psoriasis. Real world data on efficacy and safety of TNF-α blockers in the elderly with PsA are lacking. The aim of this study was to evaluate the effectiveness, through the achievement of minimal disease activity (MDA), drug discontinuation rate, and safety in elderly patients with PsA on TNF-α blockers. A multicenter, observational study was carried out in four Italian centers. The assessment of disease activity and safety were performed at the start of anti-TNF-α (T0), at 6 months (T6) and at 12 months (T12). A total of 145 PsA patients were included in the study. At baseline 68 (46.9%) patients were on etanercept, 60 (41.3%) on adalimumab, 11 (7.6%) on golimumab, and 6 (4.1%) on infliximab. All the variables concerning PsA activity showed a statistically significant improvement when comparing T6 and T12 with T0. After 6 and 12 months of therapy, respectively, 31 (22.6%) and 71 (51.8%) patients achieved MDA (p < 0.001). The drug discontinuation rate was 5.5% with a mean of 6.8 months (range 2–10 months), and it was due to lack of efficacy, adverse events, and lost to follow-up. Nine patients (6.2%) reported the onset of mild infections resolved with antimicrobial specific oral regimen without therapy interruption. TNF-α blockers are effective in the achievement of a low disease status and safe in elderly patients with PsA. Therefore, age should not be considered a limitation to their use.

Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:55–78CrossRefPubMed

Soscia E, Sirignano C, Catalano O, Atteno M, Costa L, Caso F et al (2012) New developments in magnetic resonance imaging of the nail unit. J Rheumatol Suppl 89:49–53CrossRefPubMed

Schatteman L, Mielants H, Veys EM, Cuvelier C, De Vos M, Gyselbrecht L et al (1995) Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. J Rheumatol 22:680–683PubMed

Costa L, Caso F, D'Elia L, Atteno M, Peluso R, Del Puente A et al (2012) Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol 31:711–715CrossRefPubMed

Del Puente A, Esposito A, Parisi A, Atteno M, Montalbano S, Vitiello M et al (2012) Osteoporosis and psoriatic arthritis. J Rheumatol Suppl 89:36–38CrossRefPubMed

Fiocco U, Sfriso P, Oliviero F, Lunardi F, Calabrese F, Scagliori E et al (2013) Blockade of intra-articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. Joint bone spine 80:165–170CrossRefPubMed

Huynh D, Kavanaugh A (2013) Psoriatic arthritis: current therapy and future directions. Expert Opin Pharmacother 14:1755–1764CrossRefPubMed

Scarpa R, Atteno M, Lubrano E, Provenzano G, D'Angelo S, Spadaro A et al (2011) The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clin Rheumatol 30:1063–1067CrossRefPubMedPubMedCentral

Punzi L, Podswiadek M, Sfriso P, Oliviero F, Fiocco U, Todesco S (2007) Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. Autoimmun Rev 6:524–528CrossRefPubMed

10.

Suryaprasad AG, Prindiville T (2003) The biology of TNF blockade. Autoimmun Rev 2:346–357CrossRefPubMed

11.

Salvarani C, Pipitone N, Marchesoni A, Cantini F, Cauli A, Lubrano E et al (2011) Italian society for rheumatology. Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology Clin Exp Rheumatol 29:S28–S41

12.

Krüger K, Strangfeld A, Kneitz C (2014) Safety of antirheumatic drug treatment in the elderly. Z Rheumatol 73:244–250CrossRefPubMed

13.

Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) CASPAR study group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673CrossRefPubMed

14.

Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69:48–53CrossRefPubMed

15.

Punzi L, Pianon M, Rossini P, Schiavon F, Gambari PF (1999) Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease. Ann Rheum Dis 58:226–229CrossRefPubMedPubMedCentral

16.

Esposito M, Giunta A, Mazzotta A, Zangrilli A, Babino G, Bavetta M et al (2012) Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology 225:312–319CrossRefPubMed

17.

Migliore A, Bizzi E, Laganà B, Altomonte L, Zaccari G, Granata M et al (2009) The safety of anti-TNF agents in the elderly. Int J Immunopathol Pharmacol 22:415–426CrossRefPubMed

18.

Balato N, Patruno C, Napolitano M, Patrì A, Ayala F, Scarpa R (2014) Managing moderate-to-severe psoriasis in the elderly. Drugs Aging 31:233–238CrossRefPubMed

19.

Militello G, Xia A, Stevens SR, Van Voorhees AS (2006) Etanercept for the treatment of psoriasis in the elderly. J Am Acad Dermatol 55:517–519CrossRefPubMed

20.

Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM (2010) Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol 63:448–456CrossRefPubMed

21.

Perrotta FM, Marchesoni A, Lubrano E (2016) Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J Rheumatol 43:350–355CrossRefPubMed

22.

Lubrano E, Parsons WJ, Perrotta FM (2016) Assessment of response to treatment, remission, and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors. J Rheumatol 43:918–923CrossRefPubMed

23.

Fabbroni M, Cantarini L, Caso F, Costa L, Pagano VA, Frediani B et al (2014) Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediat Inflamm 2014:862969. doi:10.1155/2014/862969 CrossRef

24.

Favalli EG, Selmi C, Becciolini A, Biggioggero M, Ariani A, Santilli D et al (2016) Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: a multi-center retrospective analysis. Arthritis Care Res (Hoboken). doi:10.1002/acr.23090

25.

Lubrano E, Perrotta FM, Marchesoni A, D'Angelo S, Ramonda R, Addimanda O et al (2015) Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study. J Rheumatol 42:258–263CrossRefPubMed

26.

Ingegnoli F, Gualtierotti R, Artusi C, Lubrano E (2014) Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk. Expert Rev Clin Immunol 10:307–315CrossRefPubMed

27.

Wick G, Jansen-Dürr P, Berger P, Blasko I, Grubeck-Loebenstein B (2000) Diseases of aging. Vaccine 18:1567–1583CrossRefPubMed

28.

Costa L, Caso F, Atteno M, Del Puente A, Darda MA, Caso P et al (2014) Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 33:833–839PubMed

29.

Atteno M, Costa L, Matarese A, Caso F, Del Puente A, Cantarini L et al (2014) The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol 33:543–547CrossRefPubMedPubMedCentral

30.

Costa L, Caso F, Atteno M, Giannitti C, Spadaro A, Ramonda R et al (2014) Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol 33:273–276CrossRefPubMed

31.

Costa L, Caso F, Del Puente A, Di Minno MN, Peluso R, Scarpa R (2016) Incidence of malignancies in a cohort of psoriatic arthritis patients taking traditional disease modifying antirheumatic drug and tumor necrosis factor inhibitor therapy: an observational study. J Rheumatol 43:2149–2154CrossRefPubMed

Medicine Matters Rheumatology

Abstract